Patient-Tailored Treatments with Anti-EGFR Monoclonal Antibodies in Advanced Colorectal Cancer: KRAS and Beyond

Publisher： Bentham Science Publishers

E-ISSN： 1873-5576|12|4|316-328

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.12, Iss.4, 2012-04, pp. : 316-328

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Anti-Egfr Therapy in Colorectal Cancer: How to Choose The Right Patient

By  

Current Drug Targets, Vol. 10, Iss. 10, 2009-10 ,pp. : 1033-1040

Bentham Science Publishers

Access to resources Recommend Favorite

KRAS Mutation Testing of Colorectal Cancer for Anti-EGFR Therapy: Dogmas Versus Evidence

By  

Current Cancer Drug Targets, Vol. 10, Iss. 8, 2010-12 ,pp. : 813-823

Bentham Science Publishers

Access to resources Recommend Favorite

Beyond RAS: The Role of Epidermal Growth Factor Receptor (EGFR) and its Network in the Prediction of Clinical Outcome During Anti-EGFR Treatment in Colorectal Cancer Patients

By  

Current Drug Targets, Vol. 15, Iss. 13, 2014-12 ,pp. : 1225-1230

Bentham Science Publishers

Access to resources Recommend Favorite

Anti-EGFR Strategy for Colorectal Cancer: Searching for the Real Target

By  

Letters in Drug Design & Discovery, Vol. 3, Iss. 8, 2006-10 ,pp. : 541-543

Bentham Science Publishers

Access to resources Recommend Favorite

Molecular Predictors of Efficacy to Anti-EGFR Agents in Colorectal Cancer Patients

By  

Current Cancer Drug Targets, Vol. 10, Iss. 1, 2010-02 ,pp. : 68-79

Bentham Science Publishers

Access to resources Recommend Favorite